Tag Archives: Ironwood Pharma

Ironwood Pharma (IRWD) Receives a Hold from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Ironwood Pharma (IRWD – Research Report), with a price target of $14. The company’s shares closed on Friday at $11.48. Selvaraju noted: “We utilize a

The CLO of Ironwood Pharma is Exercising Options

Today it was reported that the CLO of Ironwood Pharma (IRWD – Research Report), Halley Gilbert, exercised options to buy 20,449 IRWD shares at $4.89 a share, for a total transaction value of $100K. The options were close to expired

Cowen & Co. Sticks to Its Hold Rating for Ironwood Pharma (IRWD)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD – Research Report) today and set a price target of $16. The company’s shares opened today at $12.90. According to TipRanks.com, Peaker is a 4-star analyst

Ironwood Pharma (IRWD) Receives a Hold from Barclays

In a report released yesterday, Geoff Meacham from Barclays maintained a Hold rating on Ironwood Pharma (IRWD – Research Report), with a price target of $16. The company’s shares closed yesterday at $12.78, close to its 52-week low of $12.67.

Cowen & Co. Maintains a Hold Rating on Ironwood Pharma (IRWD)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD – Research Report) today and set a price target of $16. The company’s shares opened today at $12.78, close to its 52-week low of $12.67. According

Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD), Regeneron (NASDAQ: REGN) and Insmed (NASDAQ: INSM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (NASDAQ:IRWD), Regeneron (NASDAQ:REGN) and Insmed (NASDAQ:INSM). Ironwood Pharma (IRWD) H.C. Wainwright analyst Ram Selvaraju reiterated a Sell rating on Ironwood Pharma